HOME >> BIOLOGY >> NEWS
Duke's Russian Laser Making Ultraviolet Light And Gamma Rays

DURHAM, N.C. -- A record-setting Russian ultraviolet free-electron laser (FEL) has begun operating at its new home at Duke University, where investigators expect to harness it soon for medical research such as improved laser surgical techniques.

The device also is producing intense beams of gamma rays, which other physicists hope will help answer major questions in nuclear physics such as understanding thermonuclear processes inside stars like the sun.

The OK-4 optical klystron FEL, originally developed at the Budker Institute of Nuclear Physics in Novosibirsk, Russia, was moved to Duke in May 1995 to take advantage of a much more powerful 1.1 billion electron volt electron "racetrack" at Duke's Free-Electron Laser Laboratory.

After being reassembled and joined to the laboratory's electron ring, the OK-4 began producing ultraviolet laser light late on Nov. 13. Within two days, physicists had also induced the system to produce gamma rays by colliding the laser beam with the same electron beam that feeds it.

Duke's FEL Laboratory is funded by a U.S. Department of Defense program for advancing laser technology in medicine.

Free-electron lasers are like no others because they produce laser light by perturbing beams of "free" electrons that have been liberated from their normal bondage to atoms. Because electrons that provide the energy of other lasers are held within the structure of their atoms, such lasers can emit only a limited number of discrete wavelengths of light. FELs, in contrast, can be "tuned" to a large variety of different wavelengths. Also, FELs' beam pulse structures and power levels are extremely easy to manipulate.

FELs produce light by passing such free-electron beams through a series of magnets. As in all lasers, the energized electrons emit light, which is then amplified and concentrated into a sharp beam by rapidly bouncing the light between mirrors within an "optical cavity."

The O
'"/>

Contact: Monte Basgall
basgallm@mail01.adm.duke.edu
919-681-8057
Duke University
21-Nov-1996


Page: 1 2 3 4

Related biology news :

1. Russian universities receive US funding to improve basic scientific research capabilities
2. Russian, PNNL scientists advance US seed production, oil remediation
3. Russian scientists to learn Wall Street capitalism in Albuquerque, NM
4. "All my friends dream of artificial limbs": US, Russian nuclear labs work with prosthetics company to develop replacement knee
5. Multi Drug Resistant-TB: Russian Economic Collapse Will Lead To Global Spread Of "Ebola With Wings"
6. Russian Queens Bee-Little Mites Impact
7. Study Finds Russian Women, Children Not Getting Enough Iron In Their Diets
8. Laser technique used to build micro-polymeric structure on a human hair, without harming it
9. Laser technology to map industrial plant gases available through Alberta Research Council
10. Lasers create new possibilities for biological technology
11. Laser micro-scalpel yields biological insights into tissue dynamics

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Duke Russian Laser Making Ultraviolet Light And Gamma Rays

(Date:5/21/2013)... largest gathering of biomass experts , Where? ... When? 03-07 June 2013 , ... research, resource assessment, market and policy developments, manufacturing and ... world and benefiting from its 2013 edition from a ... than 60 countries, more than 240 plenary and oral ...
(Date:5/21/2013)... epigenetic modifications, which alter the way genes function ... be detected in the blood of pregnant women ... to foretell depression in the weeks after giving ... become debilitating. , The findings of the small ... in the journal Molecular Psychiatry . , ...
(Date:5/20/2013)... the effect of physical education (PE) on child weight, ... increasing the amount of time that elementary schoolchildren spent ... The study represents some of the first evidence of ... is forthcoming in the Journal of Health Economics ... can be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 , The ...
Breaking Biology News(10 mins):21st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Gym class reduces probability of obesity, study finds for first time 2
(Date:5/21/2013)... Wisc. (PRWEB) May 21, 2013 ... parts distributor , will be exhibiting for the ... Advancement of Medical Instrumentation (AAMI) 2013 Conference and ... purchase, support, distribute, and manufacture healthcare technologies. This ... in Long Beach, California. , The three-day ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 ... financial services company for clinical trials, announced today ... Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical ... investigator payment process. SpendMD ™, Aggregate ... complete solution for tracking and reporting transfer of ...
(Date:5/21/2013)... Canada (PRWEB) May 21, 2013 ... is a strong push within the industry to ... and Manufacturing Organizations and pharma companies often means ... frames. , Microtablets, developed in collaboration with Sensidose ... effective outsourcing can bring products to market sooner. ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: